RadOnc Tables

Introducing Rad Onc Tables... the app! The app interfaces live with the sheet and displays the data in a file-like format The functionality is ultra fast You can search, click links to studies, report an error App dev all thx to Matthew Culbert @culbert_md @EstesRadonc 1/

Every now and then, history calls us to stand up for justice and protect patients from relentless systemic misinformation campaigns that are literally killing them. This includes those originally funded by tobacco companies, which did everything legally possible to interfere with and obscure promising clinical data showing the life-saving efficacy of lung screening. Their key tactic? Introducing terms like “overdiagnosis” and “harms of screening” into the medical literature, which led generations of trained physicians to believe screening does more harm than good. Their highly effective strategies—carried out through influential epidemiologists in the 1980s who received large direct payments from tobacco and insurance companies to engineer doubt about early lung cancer detection—successfully delayed the implementation of annual low-dose chest CT for decades. The doubt they created persists to this day regarding the value of lung cancer screening, despite multiple NEJM publications confirming that early detection reduces lung cancer mortality more than any FDA-approved drug or device (NLST 2011, 2019; NELSON 2020). Today marks a triumphant moment in our history in tackling this decades-old issue: three (3) professional medical societies representing thoracic surgeons, radiologists, and radiation oncologists united to endorse simultaneous publication of an editorial that Annals of Internal Medicine refused to publish because it criticized a flawed paper they had published. That publication generated not only angst, but also national attention that further perpetuated concerns about the “harms of screening” in a study that was clearly designed to make lung screening appear harmful and was methodologically flawed. The societies - @STS_CTsurgery, @RadiologyACR, and @ASTRO_org - deserve commendation for their executive boards' support of this powerful message demanding higher standards for reporting the true safety of lung screening to save more lives. Annals of Thoracic Surgery authors.elsevier.com/a/1mTlgovKl6Av JACR authors.elsevier.com/a/1mTlg5VZMrOT… IJROBP redjournal.org/article/S0360-…

Imagine 4 new anticancer drugs Pallituzumab, Geriatriximab, Symptomab, & Exercizumab hit the market. They should dominate the plenary sessions at ASCO & command billion-dollar revenue. But they don't because they're nonpharmacologic & shame on us. Read our opinion piece in @JCO_ASCO ascopubs.org/doi/full/10.12…

It's time for #radoncs to get more words like this back into our vernacular. I promise, it's not that difficult. 😎

Great article advising us to use the term “toxicity” less and stick to adverse effects As such the term “toxicity” has almost completely been removed from Radonc tables and replaced with adverse effects Easy w “find and replace” redjournal.org/article/S0360-… @DrewMoghanaki @sueyom

@ZeidanMd @NRGonc @ASTRO_org Benefit in ER/PR+ Her2- on subanalysis in the study

🔥NSABP- B51 is out! Practice changing trial supporting RT de-escalation in cN1, ypN0 breast cancer 👉longer follow up desired 👉applicability across subtypes? 👉Impact of more modern systemic therapies ? @NRGonc @ASTRO_org #BreastCancer nejm.org/doi/full/10.10…

@SprakerMDPhD @Icro_Meattini @Sushilberiwal @CShahMD ITV plus 1 cm CTV plus 0.5 cm PTV The other question is, did you just do VMAT or SBRT?

A Clinical Q for Rad Onc Breast APBI, 30 Gy in 5 fractions prescribed to PTV, delivered with *daily CBCT and continuous SGRT* CTV = Clips/Seroma + 10 mm What is your PTV expansion? @Icro_Meattini @Sushilberiwal @CShahMD

@alison_tree @SprakerMDPhD @DrChowdharyMD Interesting findings regarding fiducials! Any info on whether daily or alternating days was better?

@SprakerMDPhD @DrChowdharyMD The problem with G2 tox rates is that it’s driven by a-blocker prescribing use, so a couple of high prescribing centres using fiducials might be enough to skew numbers. I put most SBRT on MRL now (no fids) and rest on CK with fids. I would treat with CBCT alone if needed.

This is a great trial and very well written report ♥️ 🙏 Will be very useful in my clinic. I am curious how many patients had fiducial-free treatment and if there are any post hoc analyses planned on that.

@SenanMD If you don’t see it in your app you may need to tap Update in the upper right corner for the newest version!

@SenanMD Only some will have them if the protocol is available publicly. Unfortunately most protocols aren’t available If available the link to the protocol will be in the reference section as in the attached pic Eventually this will have its own section

Rad Onc Tables new features: Protocols. If a protocol pdf is available, it will be linked to in the reference section We look forward to when hopefully publication of the protocol as a supplement is required and ideally a DOI 🤞🏻 Please let us know if a link becomes broken

Some dosimetry and planning info will be included in the commentary section with page number in the protocol pdf, with plans for its own section in the future

Congrats to all authors! Pfreundschuh M was the PI of the study but passed before the trial was published.

Interpretation: RT improves EFS in bulky and extranodal NHL, but this is prior to PET era RT improves EFS, PFS, and OS in PMBCL It would be useful if the authors could share outcomes when RT for PR is counted as an event, as this leads to salvage chemo in US. RT rarely used

🫀UNFOLDER published in Hemasphere 2023 Evaluated RT for bulky or extranodal disease in NHL ⬆️ 3-yr EFS 68% vs 84% No benefit in OS or PFS (But with some caveats) ✅For PLBCL, RT improved EFS, PFS, and OS ✴️Prior to PET era @jryckman3 ncbi.nlm.nih.gov/pmc/articles/P…

👋Hi friends! Check out the Sheets version of the Airtable with 53 ready-to-use site-specific templates derived from the ASTRO consensus paper (PMID 30576843). The program generates output that is compatible with all treatment planning systems. #radonc bit.ly/StructureNamin…

Merry Christmas! We have a gift to share w/you for – a radiation oncology tool to create & name (DICOM-RT), TG-263 compatible structure sets to planning cancer treatments for your patients. A #radonc #medphys thread 1/ The @IJROBP article here: sciencedirect.com/science/articl…

@_DiazaOA Thanks for your feedback!!

@RadoncTables Wait on 2nd look, their own abstract seems inequal to the table too (missing cataract). Idk who's wrong here but I apologize for the fuss 🙏🏼

Hello @RadoncTables , I know this is maybe insignificant, but the number of grade 3 toxicity in CHISEL Trial on the app seems incorrect (7, vs. supposed 8).

The European Society for Radiotherapy and Oncology (ESTRO) issued the following statement regarding the PROSPECT clinical trial for patients with resectable rectal cancer: lnkd.in/eAKgFCru #radiotherapy #radiationoncology #radonc